A quick look at Sepracor's Pipeline. Sorry about the format difficulties (this isn't exactly MSFT Word). They are organized by therapeutic category. My guess on the next partnership to be announced is for (2R,4S)-intraconazole, the Sporanex ICE. You'll find that near the bottom of the list under anti-fungals.
This is only a partial list (remember that SEPR has patented around 40 major selling drug ICE. The list below are the ones SEPR is serious about and is moving forward on (one exception that I know of is (S)-fluoxetine, they seem to have put that on the back burner in an effort to put (R)-fluoxetine, the Prozac ICE, on the front burner)
I wonder why ;-)
Dave
[Sepracor Product] [Parent Drug] [Sales (mil)] [Potential Benefits] [Status]
Respiratory Diseases
Levalbuterol HCI
Ventolin®/Proventil® $1,400 Potential for improved safety and efficacy approvable letter
(R,R)-formoterol
Foradil®/Atock® $140 Potential for rapid onset, longer duration Phase II
(-) -cetirizine
Zyrtec® $550 Potential for reduced sedation Preclinical (patent granted 5/98)
Fexofenadine
(Allegra®) Seldane® $400 Reduced cardiovascular side effects Launched
Norastemizole
Hismanal® $150 Potential for improved potency, rapid onset, longer duration, reduced cardiovascular side effects Phase III
DCL
Claritin® $1,700 Potential for improved potency Phase III
Urological Disorders
(S)-oxybutynin
Ditropan® $134 Potential for reduced side effects including: dry mouth, dizziness, nausea and palpitations Phase II
(S)-doxazosin
Cardura® $600 Potential for reduced orthostatic hypotension and improved potency Preclinical
Psychiatry/Neurology
(R)-fluoxetine
Prozac® $2,600 Potential for shorter washout and increased flexibility in treating depression Preclinical
(S)-fluoxetine
Prozac® N/A Potential prevention of migraine headaches Phase II
(+)-zopiclone
Imovane® $144 Potential for reduced anticholinergic side effects, including dry mouth Preclinical (patent issued 8/98)
(S)-sibutramine
Meridia® N/A Potential for reduced anticholinergic side effects including dry mouth and constipation Preclinical
(R)-bupropion
Zyban™ N/A Potential for reduced incidence of seizures, dry mouth and insomnia Preclinical
Gastroenterology
Norcisapride
Propulsid® $1,000 Potential for improved potency without the adverse side effects of cardiac toxicity Preclinical
(R)-ondansetron
Zofran® $600 Potential for reduced cardiovascular side effects and improved efficacy Preclinical
(S)-lansoprazole
Prevacid® $1,000 Potential for improved dosing consistency and efficacy Preclinical
(-) pantoprazole
Pantozol™ $1,000 Potential for consistent plasma levels that may lead to better efficacy and safety Preclinical
Antifungals
(2R,4S)- intraconazole
Sporanox® $550 Potential for reduced cardiovascular side effects Preclinical
(R)-lomefloxacin
Lomebact® N/A Potential for improved antimicrobial activity and decreased photosensitivity Preclinical
|
